On last trading day Ericsson (NASDAQ:ERIC) decreased -1.47% to close at $11.41. Its volatility for the week is 1.90% while volatility for the month is 1.53%. ERIC’s sales growth for past 5 years was 2.00% and its EPS growth for past 5 years was 25.80%. Ericsson (NASDAQ:ERIC) monthly performance is -8.55%. Ericsson (NASDAQ:ERIC) is mulling a string of acquisitions across segments ranging from Internet protocol network and cloud computing to TV broadcasting, as the Swedish telecom equipment maker seeks to consolidate its market position as the Nokia-Alcatel Lucent combine is set to challenge its leadership.
Gilead Sciences Inc. (NASDAQ:GILD) in last trading activity decreased -1.44% to close at $103.69. Company weekly performance is 2.28% while its quarterly performance stands at -1.75%. Gilead Sciences Inc. (NASDAQ:GILD) is -11.24% away from its 52 week high. Gilead Sciences, Inc. (NASDAQ:GILD) announced results from two studies evaluating the safety and efficacy of investigational uses of sofosbuvir-based regimens in chronic hepatitis C virus (HCV)-infected patients with genotypes 2, 3, 4 and 5. Results from the BOSON study of Sovaldi® (sofosbuvir 400 mg) in combination with ribavirin (RBV) or with pegylated interferon (PEG)/RBV demonstrated high cure rates across all patients with genotypes 2 and 3.
Alcatel Lucent SA (ADR) (NYSE:ALU) has institutional ownership stands at 4.70%. In last trading activity company’s stock closed at $3.96. Recently, Nokia agreed to buy French telecom equipment maker Alcatel-Lucent SA (ADR) (NYSE:ALU) in a deal that values Alcatel-Lucent at 15.6 billion euros or $16.6 billion on a fully diluted basis.
On last trading day Pfizer Inc. (NYSE:PFE) decreased -0.25% to close at $35.27. Its volatility for the week is 1.21% while volatility for the month is 1.32%. PFE’s sales growth for past 5 years was 0.10% and its EPS growth for past 5 years was 3.10%. Pfizer Inc. (NYSE:PFE) monthly performance is 2.83%. Pfizer recently announced that the US Food and Drug Administration (or FDA) had granted the company accelerated approval for IBRANCE and letrozole. These drugs treat a specific form of advanced breast cancer in postmenopausal women.
On last trading day Macatawa Bank Corp. (NASDAQ:MCBC) advanced 1.52% to close at $5.34. Its volatility for the week is 1.29% while volatility for the month is 1.33%. MCBC’s sales growth for past 5 years was -13.30% and its EPS growth for past 5 years was 15.80%. Macatawa Bank Corp. (NASDAQ:MCBC) monthly performance is 0.75%. Macatawa Bank Corp. (NASDAQ:MCBC) on 23 April, reported first-quarter earnings of $2.8 million. The Holland, Michigan-based bank said it had earnings of 8 cents per share. The holding company for Macatawa Bank posted revenue of $14.9 million in the period.